Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582672 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
A Phase 3 study, sponsored by Argos Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 462
- Enrollment target
NCT01582672: Clinical Trial Phase 3 study, sponsored by Argos Therapeutics.
NCT01582672 is a Phase 3 study that was terminated before completion, run by Argos Therapeutics. The registered enrollment target is 462 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582672, a Phase 3 study, was terminated before completion, sponsored by Argos Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 462 participants
- Enrollment target
Study Summary
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.
Primary Outcome
Duration from randomization to death
Interventions
- BIOLOGICAL AGS-003
- DRUG Standard Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2012-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 3 |
Why NCT01582672 stopped before completion
NCT01582672 is an interventional study that assigns participants to a tested intervention. The registered 462 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which AGS-003 is the first listed.
NCT01582672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01582672 about?
NCT01582672 is a clinical study titled "Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma". This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treat...
What is the current status of trial NCT01582672?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 462 participants. The study started on 2012-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01582672?
The interventions under investigation include: AGS-003 (BIOLOGICAL), Standard Treatment (DRUG).
Who is sponsoring clinical trial NCT01582672?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01582672's enrollment target sits among peer trials
462 821st of 2000 higher than 1,179 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia